source rebatable drug for which a payment and billing code has not previously been established the first calendar quarter to which this subsection shall apply shall be the sixth full calendar quarter after the day on which the drug was first marketed. (6) Adjustment of coinsurance With respect to coinsurance under this part with respect to a rebatable drug for which a rebate is paid under this subsection, the Secretary shall, on an annual basis, pay the individual an amount as if the coinsurance for a rebatable drug for which payment is made under this part for such individual were computed as if the payment amount incurred under this part for such drug were ratably reduced to reflect the rebate amount under this subsection for such drug. (7) Rebate deposits Amounts paid as rebates under paragraph (2)(B)(i) shall be deposited into the Federal Supplementary Medical Insurance Trust Fund established under section 1841. (8) Exemptions (A) Other rebates or discounts The Secretary shall waive the rebate under paragraph (2)(B)(i) with respect to the units of a rebatable drug of a manufacturer that is furnished to an individual, if such manufacturer, with respect to the furnishing of such units of such drug, provides for discounts under section 340B of the Public Health Service Act or for rebates under section 1927. (B) Shortages The Secretary may reduce or waive the rebate under paragraph (2)(B)(i) with respect to a rebatable drug in the case of a shortage of such drug or other exigent circumstances, as determined by the Secretary. (9) Verification surveys The Secretary may survey wholesalers and manufacturers that directly distribute rebatable drugs, when necessary, to verify the manufacturer’s average sales prices (including wholesale acquisition cost) reported under paragraph (2)(B)(ii). The Secretary may impose a civil monetary penalty in an amount not to exceed $100,000 on a wholesaler or manufacturer that refuses a request for information about charges or prices by the Secretary in connection with a survey under